Catalyst Pharmaceuticals, Inc.
CPRX
Helyezés a részvények között
#4186
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Részvényárfolyam
$31.49
Utolsó szinkronizálás: 2026-07-21
Piaci kapitalizáció
$3.85B
Változás (1 nap)
0.00%
Változás (1 év)
46.94%
Ország
US
Kereskedés Catalyst Pharmaceuticals, Inc. (CPRX)
Kategória
Healthcare
Catalyst Pharmaceuticals, Inc. (CPRX) P/B aránya
P/B arány ekkor: October 2026 TTM: 3.80
Catalyst Pharmaceuticals, Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi könyv szerinti árfolyam aránya (P/B, TTM) 3.80. 2023 végén ez az arány 4.61 volt.
P/B arány története a(z) Catalyst Pharmaceuticals, Inc. esetén 2002 és 2026 között
P/B arány az év végén
| Év | P/B arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 3.80 | 11.81% |
| 2024 | 3.40 | -26.24% |
| 2023 | 4.61 | -28.03% |
| 2022 | 6.40 | 89.14% |
| 2021 | 3.38 | 65.99% |
| 2020 | 2.04 | -53.73% |
| 2019 | 4.41 | 13.53% |
| 2018 | 3.88 | -6.36% |
| 2017 | 4.14 | 87.18% |
| 2016 | 2.21 | -38.01% |
| 2015 | 3.57 | -33.94% |
| 2014 | 5.41 | 30.46% |
| 2013 | 4.14 | 363.73% |
| 2012 | 0.89 | -88.01% |
| 2011 | 7.45 | 123.57% |
| 2010 | 3.33 | 167.55% |
| 2009 | 1.25 | -43.83% |
| 2008 | 2.22 | -16.22% |
| 2007 | 2.65 | 41.50% |
| 2006 | 1.87 | -97.79% |
| 2005 | 84.78 | -44.01% |
| 2004 | 151.41 | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | 320.54 | 0.00% |
P/B arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/B arány | P/B arány különbség | Ország |
|---|---|---|---|
| 6.251 | 64.44% |
US
|
|
| 13.2547 | 248.67% |
US
|
|
| 4.208 | 10.69% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 62.63% |
NL
|
